Australia - English - Department of Health (Therapeutic Goods Administration)

celgene australia pty ltd - thalidomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene australia pty ltd - thalidomide -

United States - English - NLM (National Library of Medicine)

celgene corporation - apremilast (unii: up7qbp99pn) (apremilast - unii:up7qbp99pn) - apremilast 10.0 mg - otezla is indicated for the treatment of adult patients with active psoriatic arthritis. otezla is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. otezla is indicated for the treatment of adult patients with oral ulcers associated with behçet's disease. otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation [see adverse reactions (6.1)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to otezla during pregnancy. information about the registry can be obtained by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/otezla/. risk summary available pharmacovigilance data with otezla use in pregnant women have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, but these data are extremely limited. bas

United States - English - NLM (National Library of Medicine)

celgene corporation - tinzaparin sodium (unii: 3s182et3ua) (tinzaparin - unii:7uq7x4y489) - injection - 20000 [iu] in 1 ml - innohep® is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium. the safety and effectiveness of innohep® were established in hospitalized patients. innohep® is contraindicated in patients with active major bleeding, in patients with (or history of) heparin-induced thrombocytopenia, or in patients with hypersensitivity to tinzaparin sodium. innohep® is contraindicated in patients aged 90 years or older with creatinine clearance ≤ 60 ml/min. patients with known hypersensitivity to heparin, sulfites, benzyl alcohol, or pork products should not be treated with innohep®.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - thalidomide, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone; purified water; gelatin; sodium lauryl sulfate - multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. thalomid is prescribed and dispensed through the thalidomide risk management pro

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - thalidomide, quantity: 150 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; sorbitan monolaurate; caramel; potable water; gelatin; sodium lauryl sulfate; pharmaceutical glaze; dimeticone - multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. multiple myeloma - thalomid in combination with melphalan and prednisone is indi

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

celgene ltd - azacitidine - powder for suspension for injection - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

celgene ltd - paclitaxel albumin - powder for suspension for infusion - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

celgene ltd - pomalidomide - capsule - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

celgene ltd - pomalidomide - capsule - 2mg